Cancer Drug Cull By NHS Sparks Demands For NICE Reform
This article was originally published in The Pink Sheet Daily
Executive Summary
Disappointed by NHS England’s decision to remove a number of high-cost drugs from the Cancer Drugs Fund, the U.K. pharma industry is focusing its firepower on reforming NICE appraisals.
You may also be interested in...
Firms May Lose Data Exclusivity Earlier Under Planned EU Adaptive Licensing Regime
Adaptive licensing is coming to Europe and, while it will be beneficial to patients, data exclusivity considerations may render it a double-edged sword to the innovative drug industry.
Cancer Drugs Fund Extended As Pharma Calls For U.K. HTA Rethink
Drug manufacturers say the announced two-year extension for Britain’s Cancer Drugs Fund would not have been needed if NICE was not so focused on cost.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.